NCT03682224View on ClinicalTrials.gov

Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

July 5, 2018

Primary Completion Date

September 3, 2022

Study Completion Date

September 3, 2022

Conditions
Non Small Cell Lung CancerLung Cancer Stage 1
Interventions
DRUG

Liposomal Bupivacaine

Liposomal Bupivacaine 1.3% (Exparel), 20 ml vial for injection, administered subcutaneously at port site

DRUG

Bupivacaine-Epinephrine

Bupivacaine-Epinephrine 0.25%, 1:200,000 (Marcaine with epinephrine), administered subcutaneously at port site

Trial Locations (1)

62781

Memorial Medical Center, Southern Illinois University-School of Medicine, Springfield

All Listed Sponsors
lead

Southern Illinois University

OTHER

NCT03682224 - Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients | Biotech Hunter | Biotech Hunter